REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR-T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells (or cells from a donor) that are specially trained to find and attack cancer ce…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 07:44 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogni…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated May 26, 2026 07:41 UTC
-
New drug cocktail aims to beat back tough blood cancers
Disease control Recruiting nowThis study is for people whose acute lymphoblastic leukemia, lymphoblastic lymphoma, or related blood cancers have returned or stopped responding to treatment. Researchers are testing a combination of six chemotherapy drugs to see if it can shrink tumors and control the disease. …
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:40 UTC
-
Promising combo tackles Hard-to-Treat leukemia
Disease control Recruiting nowThis study tests a combination of two drugs, blinatumomab and ponatinib, in adults with a specific type of acute lymphoblastic leukemia (ALL) that has the Philadelphia chromosome. The goal is to see if this combo can better control the disease, especially in patients whose cancer…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:34 UTC
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:26 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CD7 CAR T-cells) for people with T-cell cancers that have come back or not responded to standard therapy. The cells are made from the patient's own blood or from a donor. The goal is to see if this treatmen…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
Immune boosting NK cells show promise in blood cancer trial
Disease control Recruiting nowThis study tests whether giving patients their own specially matched natural killer (NK) cells after chemotherapy and a cord blood transplant can help keep blood cancers like leukemia and lymphoma from coming back. About 100 adults with various blood cancers will receive NK cells…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New nanobody CAR t therapy targets tough T-Cell cancers in early trial
Disease control Recruiting nowThis study tests a new treatment called nanobody CD5-CAR T cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer ce…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to prior treatments. The therapy…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Engineered immune cells offer new hope for Tough-to-Treat leukemia
Disease control Recruiting nowThis early-phase trial tests whether a specially engineered immune cell therapy (huCD19-CAR T cells) is safe and effective for adults with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatments. Up to 24 participants will receive their own m…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New pill shows promise for Tough-to-Treat leukemias and MDS
Disease control Recruiting nowThis study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 p…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Engineered immune cells take on tough leukemia
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for adults with acute lymphoblastic leukemia that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab to better target and kill leukemia cells. The main goal is…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New CAR t therapy trial aims to outsmart tough leukemia in kids
Disease control Recruiting nowThis study tests a special cell therapy called CAR T for children and young adults with a type of leukemia that has come back or not responded to treatment. Doctors will collect immune cells from the patient, modify them to attack cancer cells, and give them back after chemothera…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC